Under pressure: Pulmonary hypertension associated with left heart disease

European Respiratory Review

Volumn 24, Issue 138, 2015, Pages 665-673

  Farber, Harrison W ^a   Gibbs, Simon ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

BLOOD VESSEL REACTIVITY; CARDIOMYOPATHY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HUMAN; LEFT HEART DISEASE ASSOCIATED PULMONARY HYPERTENSION; LUNG ARTERY PRESSURE; PRACTICE GUIDELINE; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REVIEW; SURVIVAL RATE; VALVULAR HEART DISEASE; AGED; ALGORITHM; ARTERIAL PRESSURE; CASE REPORT; CLINICAL PATHWAY; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE FUNCTION; HYPERTENSION, PULMONARY; LUNG; LUNG WEDGE PRESSURE; MALE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY ARTERY; PULMONARY ARTERY CATHETERIZATION; RISK FACTOR;

AGED; ALGORITHMS; ARTERIAL PRESSURE; CATHETERIZATION, SWAN-GANZ; CRITICAL PATHWAYS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY ARTERY; PULMONARY WEDGE PRESSURE; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 84951197078     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0059-2015     Document Type: Review

References (64)

1. Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007; 28: 233–241.
2. Schmeisser A, Schroetter H, Braun-Dulleaus RC. Management of pulmonary hypertension in left heart disease. Ther Adv Cardiovasc Dis 2013; 7: 131–151.
3. Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation 2012; 126: 975–990.
4. Vachiery JL, Adir Y, Barbera JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013; 62: Suppl., D100–D108.
5. Fang JC, DeMarco T, Givertz MM, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult – a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2012; 31: 913–933.
6. Barnett CF, De Marco T. Pulmonary hypertension associated with left-sided heart disease. Heart Fail Clin 2012; 8: 447–459.
7. Mathier MA. Pulmonary hypertension owing to left heart disease. Clin Chest Med 2013; 34: 683–694.
8. Adir Y, Amir O. Pulmonary hypertension associated with left heart disease. Semin Respir Crit Care Med 2013; 34: 665–680.
9. Georgiopoulou VV, Kalogeropoulos AP, Borlaug BA, et al. Left ventricular dysfunction with pulmonary hypertension: Part 1: epidemiology, pathophysiology, and definitions. Circ Heart Fail 2013; 6: 344–354.
10. Guazzi M, Galiè N. Pulmonary hypertension in left heart disease. Eur Respir Rev 2012; 21: 338–346.
11. Haddad F, Kudelko K, Mercier O, et al. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis 2011; 54: 154–167.
12. Corte TJ, McDonagh TA, Wort SJ. Pulmonary hypertension in left heart disease: a review. Int J Cardiol 2012; 156: 253–258.
13. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 2010; 7: 648–659.
14. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125: 669–682
15. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000; 102: 1718–1723.
16. Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther 2009; 3: 269–287.
17. Haddad F, Doyle R, Murphy DJ, et al. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008; 117: 1717–1731.
18. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53: 1119–1126.
19. Bursi F, McNallan SM, Redfield MM, et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 2012; 59: 222–231.
20. Damy T, Goode KM, Kallvikbacka-Bennett A, et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J 2010; 31: 2280–2290.
21. Leung CC, Moondra V, Catherwood E, et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 2010; 106: 284–286.
22. Robbins IM, Newman JH, Johnson RF, et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009; 136: 31–36.
23. Cheli M, Vachiery JL. Controversies in pulmonary hypertension due to left heart disease. F1000Prime Rep 2015; 7: 07.
24. Kiefer TL, Bashore TM. Pulmonary hypertension related to left-sided cardiac pathology. Pulm Med 2011; 2011: 381787.
25. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992; 19: 48–54.
26. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl., D34–D41.
27. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903–975.
28. Watson CJ, Gupta SK, O’Connell E, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail 2015; 17: 405–415.
29. Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail 2014; 7: 367–377.
30. Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in “out-of-proportion” pulmonary hypertension. Chest 2013; 143: 758–766.
31. Tedford RJ, Beaty CA, Mathai SC, et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant 2014; 33: 289–297.
32. Wang X, Liu Y, Yuan Y, et al. Short-term prognostic factors in the patients after acute heart failure. Int J Clin Exp Med 2015; 8: 1515–1520.
33. Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl., S85–S96.
34. Rosenkranz S, Preston IR. Right heart catheterization: best practice and pitfalls in pulmonary hypertension. Eur Respir Rev 2015; 24: 642–652.
35. Robbins IM, Hemnes AR, Pugh ME, et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014; 7: 116–122.
36. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl., D42–D50.
37. Shah RV, Semigran MJ. Pulmonary hypertension secondary to left ventricular systolic dysfunction: contemporary diagnosis and management. Curr Heart Fail Rep 2008; 5: 226–232.
38. Aronson D, Eitan A, Dragu R, et al. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail 2011; 4: 644–650.
39. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37: 183–188.
40. Tampakakis E, Leary PJ, Selby VN, et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 2015; 3: 9–16.
41. Dzudie A, Kengne AP, Thienemann F, et al. Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review. BMJ Open 2014; 4: e004843.
42. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013; 1: 290–299.
43. de Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998; 32: 948–954.
44. Di Salvo TG, Mathier M, Semigran MJ, et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995; 25: 1143–1153.
45. Polak JF, Holman BL, Wynne J, et al. Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol 1983; 2: 217–224.
46. Baker BJ, Wilen MM, Boyd CM, et al. Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol 1984; 54: 596–599.
47. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573–1619.
48. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013; 128: 502–511.
49. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005; 11: 12–20.
50. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195–197.
51. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44–54.
52. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 347–354.
53. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115: 59–66.
54. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136–2144.
55. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555–1562.
56. Lüscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002; 106: 2666–2672.
57. ClinicalTrials.gov. Safety and tolerability of macitentan in subjects with combined pre- and post-capillary pulmonary hypertension due to left ventricular dysfunction (MELODY-1). https://clinicaltrials.gov/ct2/show/ NCT02070991 Date last accessed: July 21, 2015. Date last updated: September, 2015.
58. ClinicalTrials.gov. Phosphodiesterase type 5 inhibition with tadalafil changes outcomes in heart failure (PITCH-HF). https://clinicaltrials.gov/ct2/show/NCT01910389 Date last accessed: June 19, 2015. Date last updated: April, 2015.
59. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268–1277.
60. Finch KT, Stratton EA, Farber HW. Ranolazine as treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation 2013; 128: A10662.
61. Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 2014; 146: 1274–1285.
62. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015; 36: 2565–2573.
63. Friedman SE, Andrus BW. Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms. J Obes 2012; 2012: 505274.
64. Pugh ME, Newman JH, Williams DB, et al. Hemodynamic improvement of pulmonary arterial hypertension after bariatric surgery: potential role for metabolic regulation. Diabetes Care 2013; 36: e32–e33.